Kiniksa Pharmaceuticals, Ltd. (KNSA) compared with its closest peers (RARE, SUPN, AMPH, PCRX, EBS): P/E 90.1 vs industry 17.2. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Ultragenyx Pharmaceutical, Supernus Pharmaceuticals, Amphastar Pharmaceuticals, Pacira BioSciences, Emergent BioSolutions, TG Therapeutics, OPKO Health, Insmed, Catalyst Pharmaceuticals and Collegium Pharmaceutical share Kiniksa Pharmaceuticals's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.48B | -3.9 |
| Supernus Pharmaceuticals, Inc. (SUPN) | $2.56B | -73.0 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | $1.05B | 13.3 |
| Pacira BioSciences, Inc. (PCRX) | $1.06B | 72.3 |
| Emergent BioSolutions Inc. (EBS) | $331.48M | 13.3 |
| TG Therapeutics, Inc. (TGTX) | $8.72B | 18.9 |
| OPKO Health, Inc. (OPK) | $1.27B | -4.2 |
| Insmed Incorporated (INSM) | $27.66B | -27.1 |
| Catalyst Pharmaceuticals, Inc. (CPRX) | $3.85B | 17.1 |
| Collegium Pharmaceutical, Inc. (COLL) | $790.78M | 16.5 |
| Stock P/E | 90.1 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 317.3% |
| vs Industry | 422.7% |
KNSA overview · KNSA earnings · KNSA financials · KNSA KPIs · KNSA documents · KNSA ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.